Annual report for Thyrocare Technologies Ltd. for FY-2019
20-05-2019
Thyrocare Technologies Ltd - 539871 - Board recommends Dividend
Thyrocare Technologies Ltd has informed BSE that the Board of Directors of the Company at their meeting held on May 18, 2019, inter alia, decided to recommend to the Shareholders for their approval, declaration of dividend at the rate of Rs. 20.00 (Rupees Twenty only) per share (200% of the face value of Rs. 10/- each).19-05-2019
Thyrocare Technologies Ltd - 539871 - Results - Financial Results - Year Ended 31-03-2019
The Board of Directors of the Company, at their meeting held today, approved the Audited Financial Results (Stand-alone and Consolidated) for the Financial Year ended 31-03-2019 and have recommended a dividend of Rs. 20.00 (Rupees Twenty only) per share (200% of the face value of Rs. 10/- each). The Meeting concluded at 9.15 p.m. today. Besides, the Board also approved granting of Stock Options to the eligible employees of the Company for the year 2018-19, subject to approval by Members. Pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulations, 2015, the following are attached. 1. Stand-alone and Consolidated Audited Financial Results for the quarter and the financial year ended 31-03-2019. 2. Auditors' Report on the Stand-alone Financial Results for the year ended 31-03-2019. 3. Auditors' Report on the Consolidated Financial Results for the year ended 31-03-2019. The statutory auditors have issued unmodified opinion on both e Stand-alone and Consolidated Financial Results.18-05-2019
Thyrocare Technologies Ltd - 539871 - Closure of Trading Window
Please refer to our letter dated April 26, 2019 wherein we have intimated to you about closure of trading window with effect from April 26, 2019 until 48 hours after announcement of financial results for the FY 2018-19, pursuant to the provisions of SEBI (prohibition of Insider Trading) Regulations 2015, as amended, and in accordance with the Company's Code relating to prohibition of insider trading. . As intimated to you by a separate letter today, the next meeting of the Board of Directors to, inter alia, consider and approve the audited financial results for the quarter / financial year ended 31-03-2019, is scheduled to be held on Saturday, May 18, 2019. Consequently, the trading window will remain closed for trading in Company's equity shares for Directors / Designated Employees / Connected Persons covered by the said Code, upto end of the day on Tuesday, May 21, 2019.03-05-2019
Thyrocare Technologies Ltd - 539871 - Board Meeting Intimation for Board Meeting To Consider, Inter Alia, Audited Financial Results For FY 2018-19 (Stand-Alone And Consolidated), Payment Of Dividend And Issue Of Stock Options To Employees -Intimation Under Regulation 29 (1) (A) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2019 ,inter alia, to consider and approve Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a meeting of our Board of Directors of the Company will be held on Saturday, May 18, 2019, at the Corporate Office of the Company, inter alia, to consider and approve Stand-alone and Consolidated Audited Financial Results of the Company for the quarter / financial year ended March 31, 2019, to consider recommending dividend, if any, for the financial year 2018-19, and to consider granting of Employee Stock Options for the financial year ended March 31, 2019. Intimation of the above meeting of the Board of Directors is also being published in newspapers, as required under Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.03-05-2019
Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the representative(s) of SAIF Partners, would be having a meeting with us at 10.00 A.M. on Thursday, May 02, 2019 at the Corporate Office of the Company, followed by a visit to our Lab. Please note that this is subject to any last minute changes.30-04-2019
Thyrocare Technologies Ltd - 539871 - Compliance Certificate Under Reg. 7(3) Of SEBI (LODR) Regulations, For The Half Year Ended 31-03-2019
We are forwarding the Compliance Certificate issued under Regulation 7(3) of SEBI (LODR) Regulations 2015, signed by the Company Secretary of the Company and the authorised signatory of RTA27-04-2019
Thyrocare Technologies Ltd - 539871 - Submission Of Compliance Certificate In Terms Of Regulation 40 (9) Of Securities & Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations, 2015.
We are attaching Compliance Certificate dated 12-04-2019 issued by Mr. V. Suresh, Practising Company Secretary, pursuant to the Regulation 40 (9) of Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the Half-year ended March 31, 2019. Please take the same on record.27-04-2019
Thyrocare Technologies Ltd - 539871 - Closure of Trading Window
This is to inform you that pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, as amended, and in accordance with the Company's Code relating to prohibition of insider trading, the trading window of the Company will remain closed for trading in Company's equity shares for Directors / Designated Employees / Connected Persons covered by the said Code, with immediate effect, i.e. from April 26, 2019 in view of the ensuing consideration and approval of Audited Financial Results for the financial year ended 31st March 2019. The trading window shall remain closed until 48 hours after announcement of the said financial results. The actual date of re-opening of trading window will be notified in due course, as soon as the Company announces the date of the Board Meeting in which the above-mentioned financial results for the financial year ended 31st March 2019 will be considered & approved.26-04-2019
Thyrocare Technologies Ltd - 539871 - Compliances-Certificate under Reg. 54 (5) of SEBI (DP) Regulations, 1996
Sub: Certificate pursuant to Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018. We are forwarding herewith the Certificate dated 17th April 2019 issued by Link Intime India Pvt. Ltd., Registrars & Share Transfer Agents of our company, confirming compliance of the provisions of Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018. This is for your information and records.26-04-2019